PR

큐라미스, MaxCyte사와 전략적 플랫폼 계약 체결 관리자 │ 2022-12-05 HIT 5571
https://www.globenewswire.com/news-release/2022/12/05/2567044/0/en/MaxCyte-Signs-Strategic-Platform-License-with-Curamys-to-Enable-Cell-Gene-Therapies-for-the-Treatment-of-Rare-Intractable-Diseases.html https://markets.businessinsider.com/news/stocks/maxcyte-curamys-in-strategic-platform-license-deal-1031952309 https://www.lse.co.uk/news/maxcyte-inks-deal-with-south-koreas-curamys-9fsmp30t3qepw2e.html

큐라미스, MaxCyte사와 전략적 플랫폼 계약 체결

관리자 │ 2022-12-05

HIT

5571

MaxCyte-Signs-Strategic-Platform-License-with-Curamys-to-Enable-Cell-Gene-Therapies-for-the-Treatment-of-Rare-Intractable-Diseases.html

https://markets.businessinsider.com/news/stocks/maxcyte-curamys-in-strategic-platform-license-deal-1031952309

이전글	강스템, 큐라미스와 유전자세포치료제 CDMO 계약
다음글	다음글이 없습니다.